EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Alopecia Areata Associated with Dupilumab: National Database Study

Tarun Sontam, Humaira Nfn, Jodi Yanking Li, Sehar Nadeem, Katie Beier iD, Neil K Jairath, Vignesh Ramachandran

Diagnostics · 21.07.2025 · 15 (14) · 1828

DOI: 10.3390/diagnostics15141828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 21.07.2025. Verfasst von Tarun Sontam und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Texas A&M College of Medicine, Bryan, TX 77807, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alopecia areata (AA), an autoimmune condition causing non-scarring hair loss, often coexists with atopic dermatitis (AD) due to shared T-helper cell type 2 (Th2)-mediated pathways. Dupilumab, a monoclonal antibody inhibiting IL-4 and IL-13 signaling, is a cornerstone treatment for AD but has conflicting reports regarding its impact on AA, with some suggesting therapeutic benefits and others indicating AA induction.

Methods

This retrospective study, utilizing the TriNetX Research Network’s de-identified data from over 300 million patient records, investigates the association between dupilumab use and AA risk in AD patients.

Results

After propensity score matching, 23,782 dupilumab users were compared with an equal number of controls. Results revealed a statistically significant increased AA risk in dupilumab users (odds ratio: 1.436, 95% CI: 1.066–1.935, p = 0.0167) after 16 weeks. Cases occurring within 16 weeks were excluded.

Conclusions

Potential mechanisms include immune rebalancing, with Th2 suppression possibly upregulating Th1/Th17 pathways or unmasking latent AA in predisposed individuals. These findings challenge dupilumab’s potential as an AA treatment and highlight the need for vigilant monitoring, including routine scalp examinations and patient education. Future research should focus on mechanistic pathways, risk stratification, and comparative studies with other biologics to optimize personalized treatment strategies for AD and AA.

Schlagwörter

Stichwörter der Autor:innen

Th2adverse effectalopecia areataatopic dermatitisdupilumab

Autor:innen und Institutionen

  • School of Medicine, Texas A&M College of Medicine, Bryan, TX 77807, USA.
  • Department of Biology, Macaulay Honors College at Brooklyn College, Brooklyn, NY 10023, USA.
  • Department of Psychology, New York University, New York, NY 10012, USA.
  • Department of Psychology, Brooklyn College, Brooklyn, NY 10023, USA.
  • School of Medicine, Toledo Medical School, Toledo, OH 43614, USA.
  • Ronald O. Perelman Department of Dermatology, New York University, New York, NY 10016, USA.

ORCID-Profile: Katie Beier

Zitieren

APA

Sontam, T., Nfn, H., Li, J. Y., Nadeem, S., Beier, K., Jairath, N. K., & Ramachandran, V. (2025). Alopecia Areata Associated with Dupilumab: National Database Study. Diagnostics, 15(14), 1828. https://doi.org/10.3390/diagnostics15141828

Vancouver

Sontam T, Nfn H, Li JY, Nadeem S, Beier K, Jairath NK, et al. Alopecia Areata Associated with Dupilumab: National Database Study. Diagnostics. 2025;15(14):1828. doi:10.3390/diagnostics15141828

BibTeX
@article{Sontam2025,
  author = {Sontam, Tarun and Nfn, Humaira and Li, Jodi Yanking and Nadeem, Sehar and Beier, Katie and Jairath, Neil K and Ramachandran, Vignesh},
  title = {Alopecia Areata Associated with Dupilumab: National Database Study},
  journal = {Diagnostics},
  year = {2025},
  volume = {15},
  number = {14},
  pages = {1828},
  doi = {10.3390/diagnostics15141828}
}
Kostenlos starten →